J&J beats Q2 2026 estimates and raises full-year sales and EPS outlook

Johnson & Johnson reported second-quarter 2026 worldwide sales of $25.3 billion, up 6.6% reported, and adjusted EPS of $2.90, up 4.7%. Innovative Medicine grew 7.8% and MedTech 4.5%. The company raised 2026 guidance to $100.8-101.4 billion of reported sales and $11.60-11.75 of adjusted EPS, a $0.13 rise at the EPS midpoint. Shares dipped slightly in premarket trading, as the EPS beat was modest against consensus.

• Worldwide sales $25.31B, up 6.6% reported and 5.6% operational
• Adjusted EPS $2.90 (up 4.7%); reported EPS $2.27
• Innovative Medicine $16.38B (up 7.8%); MedTech $8.93B (up 4.5%)
• 2026 guidance: reported sales $100.8-101.4B; adjusted EPS $11.60-11.75

SEC filing 8-K · accession 0000200406-26-000146 · sec.gov ↗